ROBERT LOWSKY
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California C50659
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-0822
Organization information
See more information about ROBERT LOWSKY at bizstanding.comRobert Lowsky MD
300 Pasteur Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 723-9729 (Phone)
Description:
There are 10 doctors at this site. Surgery is not performed at this site.
Robert Lowsky
Stanford Cardiovascular Medical CL - Robert Lowsky MD
300 Pasteur Dr #H0101, Stanford, CA 94305
Categories:
Physicians & Surgeons
Phone:
(650) 723-0822 (Phone)
Professional information
Dr. Robert Lowsky, Stanford CA - MD (Doctor of Medicine)
Specialties:
Hematology, Hematology & Oncology
Address:
Stanford Blood/Marrow Transplnt
300 Pasteur Dr STE H0101, Stanford 94305
(650) 723-0822 (Phone)
300 Pasteur Dr STE H0101, Stanford 94305
(650) 723-0822 (Phone)
Languages:
English
Hospitals:
Stanford Blood/Marrow Transplnt
300 Pasteur Dr STE H0101, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
300 Pasteur Dr STE H0101, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
McGill University / Faculty of Medicine
McGill University / Faculty of Medicine
Enhancement Of Allogeneic Hematopoietic Stem Cell Transplantation
US Patent:
2012017, Jul 12, 2012
Filed:
Jan 10, 2012
Appl. No.:
13/347452
Inventors:
Samuel Strober - Stanford CA, US
Suparna Dutt - Palo Alto CA, US
Robert Lowsky - Stanford CA, US
Suparna Dutt - Palo Alto CA, US
Robert Lowsky - Stanford CA, US
International Classification:
A61K 35/12, A61P 35/02, A61P 35/00
US Classification:
424 9371
Abstract:
Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8 T cells as DLI following allogeneic HCT, where the cells are administered at a suitable time following transplantation. The methods provide for a more complete donor chimerism, and have the further benefit of killing tumor cells without GVHD. The memory CD8+ T cells may include one or both of central and effector memory T cells, usually both.